Cereno Scientific
Dr. Megha Ranjan is a Project Director at Cereno Scientific. Prior to this role, Dr. Ranjan held positions at MSC Nordics as a Senior Management Consultant, Tada Medical AB as a Research Analyst, PharmaACE as a Senior Consultant, and Bayer Zydus Pharma as a Medical Science Liaison. With a background in Health Management and Dental Clinical Sciences, Dr. Ranjan has experience in market research, strategy development, competitive intelligence, forecasting, and managing partnerships in the pharmaceutical and healthcare industry. Throughout her career, Dr. Ranjan has showcased expertise in various areas such as managing end-to-end projects, conducting primary market research, and developing insights for business development.
This person is not in any teams
Cereno Scientific
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.